Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386705 | 0.90 | ENPP2 (0.55) | PTGS2ENPP2FYNMAP4K4MINK1 | |
| SCHEMBL387063 | 0.84 | ENPP2 (0.61) | PTGS2ENPP2FYNMAP4K4MINK1 | |
| SCHEMBL13448493 | 0.83 | PTGS2 (0.72) | PTGS2 | |
| SCHEMBL904012 | 0.80 | PTGS2 (0.63) | PTGS2 | |
| SCHEMBL28226426 | 0.80 | ESR1 (0.70) | ESR1ESR2 | |
| SCHEMBL38659424 | 0.80 | ESR1 (0.70) | ESR1ESR2 | |
| SCHEMBL903956 | 0.79 | ENPP2 (0.53) | PTGS2ENPP2ESR1ESR2 | |
| SCHEMBL3247764 | 0.79 | PTGS2 (0.69) | PTGS2ENPP2ESR1ESR2 | |
| SCHEMBL12012445 | 0.77 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL9842662 | 0.76 | ESR1 (0.66) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | PTGS2 1372/4885ENPP2 830/4885ESR1 3449/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | PTGS2 1372/4885ENPP2 830/4885ESR1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.